Objective: We present long-term prospective data from the Abbott DBS Post-Market Study of Outcomes for Indications Over Time (ADROIT, NCT04071847) in 233 patients from 41 centres worldwide. Our results show improvements in motor testing, daily motor experience and clinical impressions from patients, caregivers and physicians, with a trend towards statistical significance.
Background: Deep brain stimulation (DBS) therapy of the subthalamic nucleus (STN) has been shown to significantly enhance motor functions in patients with Parkinson’s disease (PD) [1,2].
Method: ADROIT is a large, international, prospective, multi-centre, observational study collecting long-term safety and efficacy data on Abbott’s DBS systems. Follow-up visits are scheduled 6 months after initial programming and annually thereafter.
Results: The average baseline scores for de novo patients (67% male) with STN DBS, measured on medication and off stimulation, are as follows: Part I — 11.15, Part II — 16.30, Part III — 27.32, and Part IV — 8.2. Paired t-test analyses showed improvement and a trend toward significance from baseline (on medication/off stimulation for Part III) to follow-ups at 6 months and 1 year for MDS-UPDRS Parts II-IV [figure1]. Simultaneously, the patient, caregiver, and clinician global impression scale that evaluates all aspects of health and therapy response improved in each follow-up (6-month, 1-year; p=<.0001) indicating improved perceptions of symptoms [figure1].
Conclusion: Our results show that patients, their caregivers and physicians continue to report positive treatment response at every follow-up visit. These results offer compelling support for the sustained benefits in STN PD patients across subjective and objective measures, and reinforces the long-term value of STN DBS as an effective treatment option.
Figure 1.
References: [1] Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., … & Voges, J. (2006). A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine, 355(9), 896-908.
[2] Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., … & Deuschl, G. (2013). Neurostimulation for Parkinson’s disease with early motor complications. New England Journal of Medicine, 368(7), 610-622.
To cite this abstract in AMA style:
S. Groppa, L. Lopez-Manzanares, A. Schnitzler, S. Chen, C. Salazar, Y. Ram, M. Chung, A. Gharabaghi. 1-Year Outcomes for MDS-UPDRS Part I-IV and Clinical Impressions: Insights from a Large Real-World Prospective Study on de novo STN-DBS in Parkinson’s Disease [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/1-year-outcomes-for-mds-updrs-part-i-iv-and-clinical-impressions-insights-from-a-large-real-world-prospective-study-on-de-novo-stn-dbs-in-parkinsons-disease/. Accessed November 20, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/1-year-outcomes-for-mds-updrs-part-i-iv-and-clinical-impressions-insights-from-a-large-real-world-prospective-study-on-de-novo-stn-dbs-in-parkinsons-disease/